Nov. 23, 2024
Dear Sir or Madam, As an investor holding shares in various biotechnology companies, I would like to express my support for the proposed amendments under SR-NASDAQ-2024-045. These changes are essential for enhancing market stability and protecting investors, especially in light of recent market volatilities. Outlined Proposals: Modification of the Delisting Process, ensuring that companies failing to regain compliance with the minimum bid price requirement after a second period will be immediately delisted. Clarification of Compliance Periods, which will prevent the use of reverse stock splits as a temporary measure to meet price requirements. Automatic Delisting for companies that have conducted reverse stock splits in the preceding year. Furthermore, I strongly urge the consideration of additional measures against naked short selling. This practice, where shares are sold without actual ownership, often leads to unjustified declines in stock values, fostering market manipulations and adversely affecting market stability. Developing strict regulations in this area will provide further protection for investors and maintain fairness in trading. Thank you for considering my views on this important issue. Sincerely, Aleksei Nikolaev, M.D. Global Medical Marketing Manager